Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for pancreatic cancer: experimental drug combo enters large trial

NCT ID NCT07490301

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 02, 2026 · Updated 17 times

Summary

This large Phase 2/3 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) can help people with metastatic pancreatic cancer live longer or shrink their tumors. About 900 participants will be randomly assigned to receive either the new combination or standard care. The study is currently recruiting at sites worldwide.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
telisotuzumab adizutecan (an investigational antibody-drug conjugate) combined with FOLFOX chemotherapy
What this could lead to
If successful, this could offer a new first-line treatment option for metastatic pancreatic cancer, potentially improving response rates and survival.
What could go wrong
This is an early-to-mid stage trial; the drug is investigational and may not work better than standard care. Side effects from the combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have unresectable, metastatic histologically- or cytologically-confirmed adenocarcinoma of the pancreas * Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 * Must consent to provide archived or recently obtained tumor tissue during Screening * Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Exclusion Criteria: * Have prior systemic therapy, surgery, or radiation (except palliative radiation) in the unresectable, locally advanced or metastatic setting * Prior c-MET targeting therapy * History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis on screening chest computed tomography (CT) scan, including a history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis. * Prior bone marrow transplant, solid organ transplant, or previous clinical diagnosis of tuberculosis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic ductal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic pancreatic ductal adenocarcinoma PDAC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Austin Hospital /ID# 280283

    RECRUITING

    Melbourne, Victoria, 3084, Australia

  • Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279853

    RECRUITING

    Grand Rapids, Michigan, 49503, United States

  • China Medical University Hospital /ID# 279725

    RECRUITING

    Taichung, 40447, Taiwan

  • City Of Hope - Chicago /ID# 279814

    RECRUITING

    Zion, Illinois, 60099, United States

  • Hadassah Medical Center-Hebrew University /ID# 279411

    RECRUITING

    Jerusalem, 91120, Israel

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 279735

    RECRUITING

    Kaohsiung City, 807, Taiwan

  • Oxford University Hospital NHS Trust /ID# 279764

    RECRUITING

    Oxford, Oxfordshire, OX3 7LE, United Kingdom

  • Rambam Health Care Campus- Haifa /ID# 279409

    RECRUITING

    Haifa, 3109601, Israel

  • Seoul National University Hospital /ID# 280191

    RECRUITING

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Taipei Veterans General Hospital /ID# 279726

    RECRUITING

    Taipei, 112, Taiwan

  • Tel Aviv Sourasky Medical Center /ID# 279414

    RECRUITING

    Tel Aviv, Tel Aviv, 6423906, Israel

  • Texas Oncology - Northeast Texas /ID# 280417

    RECRUITING

    Tyler, Texas, 75702, United States

  • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 280140

    RECRUITING

    Koto-ku, Tokyo, 135-8550, Japan

  • The Chaim Sheba Medical Center /ID# 279408

    RECRUITING

    Ramat Gan, Tel Aviv, 5265601, Israel

  • UH Seidman Cancer Center /ID# 279602

    RECRUITING

    Cleveland, Ohio, 44106, United States

  • University of Chicago Medical Center /ID# 279460

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 280038

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Virginia Cancer Specialists - Fairfax /ID# 280415

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Washington University /ID# 279890

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.